Noxa/Mcl-1 balance regulates susceptibility of cells to camptothecin-induced apoptosis

Neoplasia

Volumn 9, Issue 10, 2007, Pages 871-881

  Mei, Yide ^a   Xie, Chongwei ^a   Xie, Wei ^a   Tian, Xu ^a   Li, Mei ^a   Wu, Mian ^a,b  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Apoptosis; Camptothecin; CREB; Mcl 1; Noxa

Indexed keywords

CAMPTOTHECIN; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; BIOASSAY; CELL FATE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; FUNCTIONAL PROTEOMICS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 35448964624     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07589     Document Type: Article

References (51)

1. Steller H (1995). Mechanisms and genes of cellular suicide. Science 267 (5203), 1445-1449.
2. Vaux DL and Korsmeyer SJ (1999). Cell death in development. Cell 96 (2), 245-254.
3. Johnstone RW, Ruefli AA, and Lowe SW (2002). Apoptosis: a link between cancer genetics and chemotherapy. Cell 108 (2), 153-164.
4. Danial NN and Korsmeyer SJ (2004). Cell death: critical control points. Cell 116 (2), 205-219.
5. Liu X, Kim CN, Yang J, Jemmerson R, and Wang X (1996). Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1), 147-157.
6. Zou H, Li Y, Liu X, and Wang X (1999). An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 274 (17), 11549-11556.
7. Shimizu S, Narita M, and Tsujimoto Y (1999). Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 (6735), 483-487.
8. Cory S and Adams JM (2002). The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2 (9), 647-656.
9. Puthalakath H and Strasser A (2002). Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9 (5), 505-512.
10. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, et al. (2000). The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6 (6), 1389-1399.
11. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, and Korsmeyer SJ (2001). Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292 (5517), 727-730.
12. Zong WX, Lindsten T, Ross AJ, MacGregor GR, and Thompson CB (2001). BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 15 (12), 1481-1486.
13. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, and Huang DC (2005). Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17 (3), 393-403.
14. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, and Korsmeyer SJ (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2 (3), 183-192.
15. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, and Korsmeyer SJ (2001). BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 8 (3), 705-711.
16. Cartron PF, Gallenne T, Bougras G, Gautier F, Manero F, Vusio P, Meflah K, Vallette FM, and Juin P (2004). The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell 16 (5), 807-818.
17. Harada H, Quearry B, Ruiz-Vela A, and Korsmeyer SJ (2004). Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci USA 101 (43), 15313-15317.
18. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, and Newmeyer DD (2005). BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17 (4), 525-535.
19. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, and Tanaka N (2000). Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288 (5468), 1053-1058.
20. L, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19 (11), 1294-1305.
21. Hsiang YH, Hertzberg R, Hecht S, and Liu LF (1985). Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260 (27), 14873-14878.
22. Hsiang YH and Liu LF (1988). Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48 (7), 1722-1726.
23. Li TK and Liu LF (2001). Tumor cell death induced by topoisomerase- targeting drugs. Annu Rev Pharmacol Toxicol 41, 53-77.
24. Tsao YP, Russo A, Nyamuswa G, Silber R, and Liu LF (1993). Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53 (24), 5908-5914.
25. Morris EJ and Geller HM (1996). Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol 134 (3), 757-770.
26. Shimizu T and Pommier Y (1997). Camptothecin-induced apoptosis in p53-null human leukemia HL60 cells and their isolated nuclei: effects of the protease inhibitors Z-VAD-fmk and dichloroisocoumarin suggest an involvement of both caspases and serine proteases. Leukemia 11 (8), 1238-1244.
27. Slichenmyer WJ, Nelson WG, Slebos RJ, and Kastan MB (1993). Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 53 (18), 4164-4168.
28. Uckun FM, Stewart CF, Reaman G, Chelstrom LM, Jin J, Chandan-Langlie M, Waddick KG, White J, and Evans WE (1995). In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 85 (10), 2817-2828.
29. Mei Y, Du W, Yang Y, and Wu M (2005). Puma(*)Mcl-1 interaction is not sufficient to prevent rapid degradation of Mcl-1. Oncogene 24 (48), 7224-7237.
30. Adjei PN, Kaufmann SH, Leung WY, Mao F, and Gores GJ (1996). Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32. J Clin Invest 98 (11), 2588-2596.
31. Carson JP, Zhang N, Frampton GM, Gerry NP, Lenburg ME, and Christman MF (2004). Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. Cancer Res 64 (6), 2096-2104.
32. Franke TF, Hornik CP, Segev L, Shostak GA, and Sugimoto C (2003). PI3K/Akt and apoptosis: size matters. Oncogene 22 (56), 8983-8998.
33. Marte BM and Downward J (1997). PKB/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond. Trends Biochem Sci 22 (9), 355-358.
34. Tang D, Okada H, Ruland J, Liu L, Stambolic V, Mak TW, and Ingram AJ (2001). Akt is activated in response to an apoptotic signal. J Biol Chem 276 (32), 30461-30466.
35. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, and Cohen P (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7 (4), 261-269.
36. Fernandez Y, Verhaegen M, Miller TP, Rush JL, Steiner P, Opipari AW Jr, Lowe SW, and Soengas MS (2005). Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res 65 (14), 6294-6304.
37. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, Zhang H, Hale TJ, Soengas MS, Kaufman RJ, and Wang CY (2006). Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa. J Biol Chem 281 (42), 31440-31447.
38. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al. (2005). Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65 (14), 6282-6293.
39. Du K and Montminy M (1998). CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 273 (49), 32377-32379.
40. Lallemand C, Blanchard B, Palmieri M, Lebon P, May E, and Tovey MG (2007). Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB. Oncogene 26 (3), 328-338.
41. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, et al. (2003). Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. Cancer Res 63 (5), 1000-1011.
42. Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, Fukui Y, Nonomura Y, and Matsuda Y (1993). Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem 268 (34), 25846-25856.
43. Hershko T and Ginsberg D (2004). Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279 (10), 8627-8634.
44. Hijikata M, Kato N, Sato T, Kagami Y, and Shimotohno K (1990). Molecular cloning and characterization of a cDNA for a novel phorbol-12-myristate-13- acetate-responsive gene that is highly expressed in an adult T-cell leukemia cell line. J Virol 64 (10), 4632-4639.
45. Kim JY, Ahn HJ, Ryu JH, Suk K, and Park JH (2004). BH3-only protein Noxa is a mediator of hypoxic cell death induced by hypoxia-inducible factor 1alpha. J Exp Med 199 (1), 113-124.
46. Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, Waterhouse NJ, and Green DR (2003). p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10 (4), 451-460.
47. Sesto A, Navarro M, Burslem F, and Jorcano JL (2002). Analysis of the ultraviolet B response in primary human keratinocytes using oligonucleotide microarrays. Proc Natl Acad Sci USA 99 (5), 2965-2970.
48. Shibue T, Takeda K, Oda E, Tanaka H, Murasawa H, Takaoka A, Morishita Y, Akira S, Taniguchi T, and Tanaka N (2003). Integral role of Noxa in p53-mediated apoptotic response. Genes Dev 17 (18), 2233-2238.
49. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, and Yang-Yen HF (1999). The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19 (9), 6195-6206.
50. Zhan Q, Bieszczad CK, Bae I, Fornace AJ Jr, and Craig RW (1997). Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene 14 (9), 1031-1039.
51. Alves NL, Derks IA, Berk E, Spijker R, van Lier RA, and Eldering E (2006). The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 24 (6), 703-716.